InflammaSense gains significant federal backing through the ARPA-H CIRCLE Award to advance its wearable sensor technology for critical care monitoring in a 200-patient clinical study.
InflammaSense has been selected as a performer for the ARPA-H CIRCLE Award, securing up to $38 million in non-dilutive funding to advance its clinical diagnostic technology. This award provides critical validation for the company's VITALx-patch wearable sensor and ARC cascade-endotyping classifier, which are designed to monitor autonomic and inflammatory signatures in critically ill patients.
The study aims to measure autonomic and inflammatory signatures in up to 200 critically ill patients using the VITALx-patch and ARC classifier.
The award provides up to $38 million in funding to support the development and testing of InflammaSense's diagnostic technology.
Pre-revenue medtech firm InflammaSense, Inc. has been selected for the ARPA-H CIRCLE Award, securing up to $38 million in funding. The company will deploy its VITALx-patch wearable sensor to monitor inflammatory signatures in 200 critically ill patients.
The project aims to measure autonomic and inflammatory signatures in up to 200 critically ill patients using the VITALx-patch wearable sensor and the ARC cascade-endotyping classifier.